Back to Search
Start Over
Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook
- Source :
- GlobeNewswire. September 6, 2023
- Publication Year :
- 2023
-
Abstract
- Total revenue and other income nearly doubled (EUR2,4 million, +95%) R&D progress across the board, including initiation of the 4-arm Phase 2 clinical trial for Alenura[sup.TM], targeting IC/BPS, a condition [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.763553110